Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis 12 28 51 41 14 69
Gastroparesis Syndrome 12
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD10 32 K31.84
ICD9CM 34 536.3
MeSH 41 D018589
NCIt 46 C80512
UMLS 69 C0152020

Summaries for Gastroparesis

MalaCards based summary : Gastroparesis, also known as gastroparesis syndrome, is related to stomach disease and dyspepsia, and has symptoms including persistent vomiting, lassitude and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Domperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, testes and pancreas, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Gastroparesis (GP also called delayed gastric emptying) is a medical condition consisting of a paresis... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 stomach disease 30.4 CCK GAST GHRL MLN MLNR
2 dyspepsia 29.5 CCK GHRL HTR3A
3 duodenogastric reflux 29.3 CCK GAST MLN
4 body mass index quantitative trait locus 11 29.1 CCK DRD2 GHRL GHSR
5 migraine with or without aura 1 29.0 CYP2D6 DRD2 HTR3A
6 anxiety 28.7 CCK CYP2D6 HTR3A
7 constipation 28.5 CCK GAST HTR3A MLN MLNR
8 brittle diabetes 10.9
9 galactorrhea 10.4 CYP2D6 DRD2
10 codeine toxicity 10.4 ABCB1 CYP2D6
11 tardive dyskinesia 10.4 CYP2D6 DRD2
12 functional colonic disease 10.3 MLN MLNR
13 neuroleptic malignant syndrome 10.3 CYP2D6 DRD2
14 colonic pseudo-obstruction 10.2 MLN MLNR
15 paralytic ileus 10.1 ABCB1 CCK
16 pancreatic gastrinoma 10.1 GAST GHSR
17 opioid abuse 10.1 CCK DRD2
18 non-functioning pancreatic endocrine tumor 10.1 GAST GHRL
19 diabetes mellitus 10.1
20 duodenal gastrinoma 10.1 CCK GAST
21 nasal cavity adenocarcinoma 10.1 CCK GAST
22 pancreatic cholera 10.1 CCK GAST
23 pylorospasm 10.0 GAST GHRL MLN
24 episodic pain syndrome, familial, 1 10.0
25 radiation cystitis 10.0 HMOX1 NOS1
26 opioid addiction 10.0 ABCB1 CCK DRD2
27 neuronitis 10.0
28 neuropathy 10.0
29 postcholecystectomy syndrome 10.0 CCK GAST MLN
30 cataract 14, multiple types 10.0 CCK GAST
31 body mass index quantitative trait locus 9 9.9
32 body mass index quantitative trait locus 8 9.9
33 body mass index quantitative trait locus 7 9.9
34 body mass index quantitative trait locus 12 9.9
35 body mass index quantitative trait locus 14 9.9
36 body mass index quantitative trait locus 18 9.9
37 pancreatitis 9.9
38 disease of mental health 9.9 CCK CYP2D6 DRD2
39 pancreatic steatorrhea 9.9 CCK GHRL
40 restless legs syndrome 9.9 DRD2 HMOX1 NOS1
41 small cell cancer of the lung 9.9
42 body mass index quantitative trait locus 4 9.9
43 body mass index quantitative trait locus 10 9.9
44 fibrosis of extraocular muscles, congenital, 1 9.8
45 lung cancer 9.8
46 esophagitis 9.8
47 autonomic dysfunction 9.8
48 dysphagia 9.8
49 eating disorder 9.8 CCK DRD2 GHRL
50 obsessive-compulsive disorder 9.8 CYP2D6 DRD2 HTR3A

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


persistent vomiting, lassitude, signs and symptoms, digestive, ophthalmoplegia, hemiplegia

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.17 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.17 GHSR
3 Decreased viability GR00381-A-3 9.17 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 HTR3A ABCB1 NOS1 CCK DRD2 GHRL
2 adipose tissue MP:0005375 9.72 HMOX1 NOS1 DRD2 GHRL GHSR
3 digestive/alimentary MP:0005381 9.63 ABCB1 NOS1 DRD2 GAST GHRL GHSR
4 endocrine/exocrine gland MP:0005379 9.56 HTR3A ABCB1 NOS1 CCK DRD2 GAST
5 homeostasis/metabolism MP:0005376 9.28 HMOX1 HTR3A ABCB1 NOS1 CCK DRD2

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 57808-66-9 3151
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 657311 5754
6
Tadalafil Approved, Investigational Phase 4,Phase 2 171596-29-5 110635
7
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
8
Ticagrelor Approved Phase 4 274693-27-5 9871419
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12 Mosapride Investigational Phase 4 112885-41-3
13
Butyric Acid Experimental, Investigational Phase 4,Phase 2 107-92-6 264
14 Anticoagulants Phase 4
15 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Calcium, Dietary Phase 4
18 Chelating Agents Phase 4
19 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
21 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
24
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
25 Serotonin Agents Phase 4,Phase 3,Phase 2
26 glucagon Phase 4
27 Glucagon-Like Peptide 1 Phase 4
28 Antacids Phase 4,Phase 1
29 Anti-Ulcer Agents Phase 4,Phase 1
30 Proton pump inhibitors Phase 4
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
32 Hormones Phase 4,Phase 1,Phase 2
33 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Incretins Phase 4,Phase 1,Phase 2
35 Cortisol succinate Phase 4,Phase 2
36 Hormone Antagonists Phase 4,Phase 2,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
38 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2
39 Hydrocortisone acetate Phase 4,Phase 2
40 Hydrocortisone-17-butyrate Phase 4,Phase 2
41 Central Nervous System Depressants Phase 4,Phase 2
42 Psychotropic Drugs Phase 4,Phase 3,Phase 2
43 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2
44 Phosphodiesterase Inhibitors Phase 4,Phase 2
45 Vasodilator Agents Phase 4,Phase 2
46 Analgesics Phase 4,Phase 2
47 Analgesics, Non-Narcotic Phase 4
48 Antipyretics Phase 4
49 Antipsychotic Agents Phase 4,Phase 2
50 Tranquilizing Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 237)

# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4 Mosapride;domperidone
3 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
4 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
5 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed NCT00492622 Phase 4 Immediate-release omeprazole;Delayed-release omeprazole
6 Limited Access Protocol for the Use of Oral Cisapride Completed NCT02524496 Phase 4
7 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
8 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Recruiting NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
9 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
10 An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
11 An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4 Cisapride;Placebo
12 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4 Haloperidol;Conventional Therapy
13 Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis Terminated NCT00390975 Phase 4 Tegaserod
14 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
15 An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects Terminated NCT02793154 Phase 4 Exenatide;Albiglutide
16 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
17 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4 tadalafil
18 Sancuso® for Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
19 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
20 A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Unknown status NCT01460550 Phase 3
21 Nortriptyline for Idiopathic Gastroparesis Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
22 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
23 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Completed NCT02025725 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
24 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Completed NCT02025751 Phase 3 Metoclopramide Nasal Spray;Placebo Nasal Spray
25 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed NCT01149369 Phase 3 Aprepitant;Placebo
26 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Completed NCT01379183 Phase 2, Phase 3 Erythromycin;Placebo
27 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Recruiting NCT03285308 Phase 3 Relamorelin;Placebo
28 Prucalopride Versus Placebo in Gastroparesis Recruiting NCT02031081 Phase 2, Phase 3 Prucalopride;Placebo
29 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3 Domperidone
30 Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve Recruiting NCT02524626 Phase 3
31 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Active, not recruiting NCT02457156 Phase 3 Octreotide
32 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 Enrolling by invitation NCT03383146 Phase 3 Relamorelin;Placebo
33 A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 Enrolling by invitation NCT03420781 Phase 3 Relamorelin;Placebo
34 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
35 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02 Not yet recruiting NCT03426345 Phase 3 Relamorelin;Placebo
36 REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY) Not yet recruiting NCT03030170 Phase 3
37 Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy Not yet recruiting NCT03419676 Phase 3
38 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
39 PoLyethylene Glycolic Acid Mesh reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial) Not yet recruiting NCT03331718 Phase 3 PGA mesh reinforcement
40 Acupuncture for Diabetic Gastroparesis Suspended NCT00470795 Phase 3
41 Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus Terminated NCT00228891 Phase 2, Phase 3
42 The Use of Domperidone for Gastroparesis Withdrawn NCT01378884 Phase 3 Domperidone
43 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
44 Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Withdrawn NCT00228904 Phase 2, Phase 3
45 Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People Unknown status NCT02308254 Phase 1, Phase 2 Lixisenatide;Placebo
46 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
47 Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment Unknown status NCT01993680 Phase 2 Pyridostigmine bromide;fludrocortisone
48 The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01428050 Phase 2 3% NaCl Solution;Lactated Ringers Solution
49 External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD) Unknown status NCT01634971 Phase 2
50 The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study Completed NCT02267525 Phase 2 Velusetrag;Placebo

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Genetic tests related to Gastroparesis:

# Genetic test Affiliating Genes
1 Gastroparesis 28

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

38
Small Intestine, Testes, Pancreas, Lung, Colon, Heart, Kidney

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 670)
# Title Authors Year
1
Gastric per-oral endoscopic myotomy for refractory gastroparesis: a detailed description of the procedure, our experience, and review of the literature. ( 29435752 )
2018
2
Glycosylated hemoglobin level may predict the severity of gastroparesis in diabetic patients. ( 29111279 )
2018
3
LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells. ( 29317209 )
2018
4
Challenges in defining, diagnosing, and treating diabetic gastroparesis. ( 29198995 )
2018
5
Intravenous immunoglobulin in drug and device refractory patients with the symptoms of gastroparesis-an open-label study. ( 29205691 )
2018
6
A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. ( 29153755 )
2018
7
Therapeutic response to domperidone in gastroparesis: AA prospective study using the GCSI-daily diary. ( 29110425 )
2018
8
Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. ( 29111115 )
2018
9
Delivery of Mesenchymal Stem Cells from Gelatin-Alginate Hydrogels to Stomach Lumen for Treatment of Gastroparesis. ( 29414870 )
2018
10
Gastric per-oral endoscopic pyloromyotomy in the treatment of refractory gastroparesis: Report on the first case performed in Mexico. ( 28684033 )
2017
11
Is There a Role for Enterohormones in the Gastroparesis of Critically Ill Patients? ( 28737574 )
2017
12
Efficacy and Safety of Relamorelin in Diabetics with Symptoms of Gastroparesis:A Randomized, Placebo-Controlled Study. ( 28760384 )
2017
13
Emergency Department Burden of Gastroparesis in the United States, 2006 to 2013. ( 29256990 )
2017
14
Laparoscopic treatment of gastroparesis: a single center experience. ( 28888796 )
2017
15
Chronic opioids in gastroparesis: Relationship with gastrointestinal symptoms, healthcare utilization and employment. ( 29142478 )
2017
16
Hot Off the Press: SGEM#196: Gastroparesis-I Feel Like Throwing Up. ( 29245179 )
2017
17
Effectiveness and feasibility of robotic gastric neurostimulator placement in patients with refractory gastroparesis. ( 28730536 )
2017
18
Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( 28646590 )
2017
19
Proof of concept: short-term non-invasive cervical vagus nerve stimulation in patients with drug-refractory gastroparesis. ( 29067158 )
2017
20
Gastroparesis: pharmacotherapy and cardiac risk. ( 29157021 )
2017
21
"First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. ( 28932929 )
2017
22
The Long-Term Efficacy and Safety of Pyloroplasty Combined with Gastric Electrical Stimulation Therapy in Gastroparesis. ( 27896652 )
2017
23
Impaired insulin/IGF-1 is responsible for diabetic gastroparesis by damaging myenteric cholinergic neurons and interstitial cells of Cajal. ( 28931726 )
2017
24
Understanding the Differences Between Gastroparesis and Gastroparesis-Like Syndrome: Filling a GaPing Hole? ( 28776142 )
2017
25
Vitamin C Improves Gastroparesis in Diabetic Rats: Effects on Gastric Contractile Responses and Oxidative Stress. ( 28639130 )
2017
26
POEMs for gastroparesis. ( 27986106 )
2017
27
A quantified risk-scoring system and rating model for postsurgical gastroparesis syndrome in gastric cancer patients. ( 28743171 )
2017
28
Modified Laparoscopic Pyloroplasty During Laparoscopic Splenectomy and Azygoportal Disconnection for the Prevention of Postoperative Gastroparesis. ( 28689488 )
2017
29
Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. ( 28066953 )
2017
30
Exploring the Diabetic Gastroparesis Patient Experience: Patient Exit Interviews. ( 29079987 )
2017
31
Endoscopic Pyloromyotomy for the Treatment of Severe Refractory Diabetic Gastroparesis. ( 28050040 )
2017
32
Radiation induced gastroparesis-case report and literature review. ( 28890828 )
2017
33
Tailored approach to gastroparesis significantly improves symptoms. ( 28779255 )
2017
34
Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. ( 28872760 )
2017
35
Reactive oxygen species overproduction and MAP kinase phosphatase-1 degradation are associated with gastroparesis in a streptozotocin-induced male diabetic rat model. ( 29094779 )
2017
36
Gastric peroral endoscopic myotomy for gastroparesis, after botulinum toxin injection. ( 28759929 )
2017
37
Exploration of the psychosocial issues associated with gastroparesis: A qualitative investigation. ( 28071866 )
2017
38
Patients with symptoms of delayed gastric emptying have a high prevalence of oesophageal dysmotility, irrespective of scintigraphic evidence of gastroparesis. ( 29177065 )
2017
39
Gastroparesis: Medical and Therapeutic Advances. ( 28721575 )
2017
40
Outcomes of High-Frequency Gastric Electric Stimulation for the Treatment of Severe, Medically Refractory Gastroparesis in Finland. ( 29268656 )
2017
41
Gastric peroral endoscopic pyloromyotomy as a salvage therapy for refractory gastroparesis: a case series of different subtypes. ( 28028897 )
2017
42
Analysis of the Relationship between<i>Helicobacter pylori</i>Infection and Diabetic Gastroparesis. ( 29133755 )
2017
43
Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. ( 29161307 )
2017
44
Yield of Endoscopy in Pediatric Gastroparesis. ( 28644345 )
2017
45
Healthcare utilization and costs associated with gastroparesis. ( 28706426 )
2017
46
Functional dyspepsia and gastroparesis. ( 28832359 )
2017
47
Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. ( 27010235 )
2016
48
Immunomodulation for treatment of drug and device refractory gastroparesis. ( 27014566 )
2016
49
Role and efficacy of chronic intermittent insulin intravenous infusion therapy (CIIIT) in patients with diabetic gastroparesis. ( 27727602 )
2016
50
Towards a better drug for gastroparesis- the problem with a "moving" target. ( 27215652 )
2016

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 8.92 CCK DRD2 GHRL HTR3A

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.93 CCK GAST GHRL MLN
2 response to hypoxia GO:0001666 9.81 DRD2 HMOX1 NOS1
3 excitatory postsynaptic potential GO:0060079 9.72 DRD2 GHRL HTR3A
4 response to nicotine GO:0035094 9.65 DRD2 HMOX1
5 response to cocaine GO:0042220 9.65 DRD2 HTR3A
6 hormone-mediated signaling pathway GO:0009755 9.64 GHRL GHSR
7 negative regulation of blood pressure GO:0045776 9.64 DRD2 NOS1
8 decidualization GO:0046697 9.62 GHRL GHSR
9 response to food GO:0032094 9.62 GAST GHSR
10 regulation of sodium ion transport GO:0002028 9.61 DRD2 NOS1
11 actin polymerization or depolymerization GO:0008154 9.61 GHRL GHSR
12 positive regulation of sprouting angiogenesis GO:1903672 9.6 GHRL GHSR
13 positive regulation of vascular endothelial cell proliferation GO:1905564 9.59 GHRL GHSR
14 adult feeding behavior GO:0008343 9.58 GHRL GHSR
15 positive regulation of growth hormone secretion GO:0060124 9.58 DRD2 GHRL
16 negative regulation of appetite GO:0032099 9.57 CCK GHSR
17 negative regulation of interleukin-1 beta production GO:0032691 9.56 GHRL GHSR
18 growth hormone secretion GO:0030252 9.54 GHRL GHSR
19 positive regulation of growth GO:0045927 9.52 GHRL GHSR
20 negative regulation of tumor necrosis factor secretion GO:1904468 9.51 GHRL GHSR
21 G-protein coupled receptor signaling pathway GO:0007186 9.5 CCK DRD2 GAST GHRL GHSR MLN
22 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.49 GHRL GHSR
23 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.48 GHRL GHSR
24 positive regulation of appetite GO:0032100 9.46 GHRL GHSR
25 regulation of transmission of nerve impulse GO:0051969 9.43 GHRL GHSR
26 positive regulation of multicellular organism growth GO:0040018 9.43 DRD2 GHRL GHSR
27 positive regulation of eating behavior GO:1904000 9.4 GHRL GHSR
28 regulation of gastric motility GO:1905333 9.37 GHRL GHSR
29 positive regulation of small intestine smooth muscle contraction GO:1904349 9.32 GHRL GHSR
30 positive regulation of small intestinal transit GO:0120058 9.16 GHRL GHSR
31 negative regulation of insulin secretion GO:0046676 8.8 DRD2 GHRL GHSR
32 signal transduction GO:0007165 10.13 CCK DRD2 GAST GHSR HTR3A MLNR

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.33 CYP2D6 HMOX1 NOS1
2 growth hormone-releasing hormone receptor activity GO:0016520 8.96 GHSR MLNR
3 hormone activity GO:0005179 8.92 CCK GAST GHRL MLN

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....